BioLineRx Ltd. - American Depositary Shares (BLRX) analyst actions
Rating and price-target actions on BLRX in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the BLRX overview →
2 measured BLRX analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma | Press release | +0.00% | +0.00% | |
| BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) | Press release | -4.79% | -10.73% |
Keep exploring
More BLRX: earnings → · SEC filings → · BLRX overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share) (FMS) | 150 | -0.01% | 48% |
| Sol-Gel Technologies Ltd. - Ordinary Shares (SLGL) | 149 | 0.00% | 42% |
| INMED PHARMACEUTICALS (IMLFF) | 148 | 0.00% | 48% |
| Akari Therapeutics Plc - American Depositary Shares (AKTX) | 146 | 0.00% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.